Cellebrite DI Ltd. (CLBT) — Fundamental Analysis & Key Financial Ratios

As of , Kaplio rates Cellebrite DI (CLBT) expensive: it trades at 51.9 times earnings, 62 % above its sector median (32.0); it is only compared with its sector. Its results disappoint and it pays no dividend.

“Cheap” or “expensive” is measured against its own history and its sector; it is not an estimate of its value or a recommendation.

Educational analysis with public data, not a recommendation. How it is calculated →

See the 75 cheap companies in Technology

Cellebrite DI Ltd. (CLBT) — Price $12.15 (closing price, October 30, 2026) — Technology — Software - Infrastructure — NASDAQ

Latest reported results:

Cellebrite DI Ltd. (CLBT) is a publicly traded company in the Technology — Software - Infrastructure industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.

Cellebrite DI Ltd. delivers specialized digital intelligence solutions crafted for legally authorized investigations. Their comprehensive DI platform enables users to efficiently gather, scrutinize, interpret, and oversee digital information throughout the investigative process.

Is Cellebrite DI Ltd. stock overvalued or undervalued in 2026?

Cellebrite DI Ltd. (CLBT) trades at 51.9× earnings (P/E), above the median of the 314 technology companies over $2bn in Kaplio's universe. At its sector median (32.0×) $7 (-38 %).

Kaplio overview: Cellebrite DI Ltd.

Market cap $3B · 52 weeks $10 – $19 (37 % below the high) · P/E 51.9× · 2027 expected P/E 32.4× · Dividend none · Next earnings November 12, 2026 · expected EPS $0.09 · Closing price, Oct 30 · accounts published Aug 13.

What would it be worth at its usual multiples?

At its sector median (32.0×) $7 (-38 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.

What matters in technology: 5 of 8 pass

Against its peers (reference peers) — Cellebrite DI Ltd.: P/E 52.0×; EV/EBITDA 25.8×; ROIC 6.9 %; $3.1B. Axon Enterprise, Inc. (P/E 177×; EV/EBITDA 75.4×; ROIC 1.1 %; $34.8B), Teradata Corporation (P/E 7.2×; EV/EBITDA 4.1×; ROIC 11.6 %; $3.2B), NetScout Systems, Inc. (P/E 23.2×; EV/EBITDA 11.4×; ROIC 6.0 %; $2.8B).

Analysis: · Data: companies' official filings · Updated

Profitability

Return on Equity11.87%
Return on Invested Capital6.93%
Return on Assets5.91%
Gross Margin82.96%
Operating Margin10.99%
Net Margin11.43%

Financial Health

Debt / Equity0.04
Current Ratio1.60
Piotroski F-Score5
Altman Z-Score6.82

Price Performance

1 month+9.07%
3 months-17.63%
Year-to-date-32.61%
1 year-28.78%
3 years+77.37%
5 years+8.10%

Related companies: AXON · MSFT · PLTR · ORCL · PANW · 0KF5.L · CRWD · 0IR9.L

Explore sector: Technology · Software - Infrastructure

More sections of CLBT: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events

Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks